Maggie Fick

London

European Pharmaceuticals Industry Correspondent at Reuters

European Pharmaceuticals Industry correspondent @Reuters. Previously reporting from Africa and the Middle East for @Reuters @FT @AP since 2010.

Featured in: Favicon

reuters.com (+1) Favicon

globo.com

msn.com

nytimes.com Favicon

yahoo.com (+15) Favicon

businessinsider.com Favicon

dailymail.co.uk Favicon

terra.com.br Favicon

indiatimes.com (+1) Favicon

independent.co.uk + 81 more

Articles

Novo Nordisk shares up on hopes for recovery of Wegovy weight-loss drug sales in U.S.

1 week ago | theglobeandmail.com | Jacob Gronholt-Pedersen |Maggie Fick
Novo Nordisk's CFO Sceptical Trump Executive Order on Drug Manufacturing Can Cut Timelines

1 week ago | money.usnews.com | Maggie Fick |Jacob Gronholt-Pedersen

By Maggie Fick and Jacob Gronholt-PedersenLONDON/COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to reduce the time it takes to approve pharmaceutical plants in the country will significantly change timelines for the pharma industry.
Novo Nordisk latest drugmaker to drop gender goals in US

1 week ago | ca.marketscreener.com | Jacob Gronholt-Pedersen |Maggie Fick

COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for senior leadership positions in its U.S. business following executive orders by President Donald Trump to stop diversity, equity and inclusion initiatives.
Novo Nordisk latest drugmaker to drop gender goals in US

1 week ago | marketscreener.com | Jacob Gronholt-Pedersen |Maggie Fick

COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for senior leadership positions in its U.S. business following executive orders by President Donald Trump to stop diversity, equity and inclusion initiatives.
Novo Nordisk cuts 2025 outlook as Wegovy obesity drug sales slow

1 week ago | marketscreener.com | Jacob Gronholt-Pedersen |Maggie Fick

COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on Wednesday, ending a four-year stretch of steady guidance increases since the launch of its Wegovy weight-loss drug, as U.S. prescriptions ceased to grow. The company said first-quarter sales of its first-to-market weight-loss drug Wegovy were 17.36 billion Danish crowns ($2.64 billion), declining 13% from the previous quarter, and below the 18.7 billion crowns expected by analysts.
Novo Nordisk hopes to see US Wegovy sales recover soon

1 week ago | marketscreener.com | Jacob Gronholt-Pedersen |Maggie Fick

COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts. U.S. pharmacies that have been allowed to produce compounded copies of Wegovy and Ozempic due to a shortage of supply have been given until May 22 to stop, following a review by the U.S. Food and Drug Administration (FDA).
GSK 'Well Positioned' for Potential Tariffs After Beating Forecasts

1 week ago | money.usnews.com | Pushkala Aripaka |Maggie Fick

By Pushkala Aripaka and Maggie Fick(Reuters) - GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts and dual sourcing for its medicines, but offered few details. The British drugmaker reported stronger-than-expected first-quarter results and reaffirmed its 2025 outlook, sending its shares up 3.8% by 0900 GMT. They were among the top gainers on London's FTSE 100 index, which was up 0.02%.
GSK 'well positioned' for potential tariffs after beating forecasts

2 weeks ago | marketscreener.com | Pushkala Aripaka |Maggie Fick

(Reuters) - GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts and dual sourcing for its medicines, but offered few details. The British drugmaker reported stronger-than-expected first-quarter results and reaffirmed its 2025 outlook, sending its shares up 3.8% by 0900 GMT. They were among the top gainers on London's FTSE 100 index, which was up 0.02%.
AstraZeneca says potential US tariffs manageable, faces another China fine

2 weeks ago | marketscreener.com | Maggie Fick |Pushkala Aripaka

(Reuters) - AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, asserting it would maintain its 2025 forecasts if the levies end up being in line with other sectors. The tariffs and their erratic rollout by President Donald Trump have heightened fears of global supply chain disruptions, roiling industries that are heavily focused on the United States, the world's biggest consumer market.
AstraZeneca faces new import tax fine in China of up to US$8-million

2 weeks ago | theglobeandmail.com | Pushkala Aripaka |Maggie Fick